Abstract:We read with interest the case report by Zander et al. describing a patient with thymoma that was responsive to low-dose pembrolizumab.1Zander T. Aebi S. Rast A.C. et al.Response to pembrolizumab in a patient with relapsing thymoma.J Thorac Oncol. 2016; 11: e147-e149Abstract Full Text Full Text PDF PubMed Scopus (28) Google Scholar High rates of programmed cell death 1 ligand 1 (PD-L1) expression have been found in thymic epithelial tumors and are associated with more aggressive types and advanced stages at diagnosis.2Katsuya Y. Fujita Y. Horinouchi H. Ohe Y. Watanabe S. Tsuta K. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.Lung Cancer. 2015; 88: 154-159Abstract Full Text Full Text PDF PubMed Scopus (124) Google Scholar However, the efficacy of programmed cell death 1 (PD-1)/PD-L1 blockade for thymoma or thymic carcinoma has not yet been investigated in large-scale clinical trials. Another case demonstrating response to pembrolizumab in a patient with thymic epithelial tumor has been published.3Yang Y. Ding L. Wang P. Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases.J Thorac Dis. 2016; 8: E535-E537Crossref PubMed Scopus (14) Google Scholar We present a case of thymic carcinoma with partial response to nivolumab. Thymic carcinoma with squamous cell differentiation was diagnosed in a 62-year-old woman (Fig. 1). Her disease was staged cT4N3M1 at diagnosis, with metastases in the mediastinal, bilateral hilar, and supraclavicular lymph nodes, as well as in the lung, pleura, and pericardium. Chemotherapy with paclitaxel and cisplatin (cisplatin, 70 mg/m2 once on day 1, and paclitaxel, 60 mg/m2 once on days 1 and 8, repeated every 21 days) led to a partial response. However, progression of the primary mediastinal tumor, pleural seeding, new right hilar lymphadenopathy, and a new liver metastasis were found by computed tomography (CT) scan after a total of eight cycles of paclitaxel and cisplatin. Four cycles of doxorubicin and cyclophosphamide (doxorubicin, 50 mg/m2, and cyclophosphamide, 500 mg/m2, once every 3 weeks) thereafter resulted in stable disease in the mediastinal mass, hilar nodes, and pleural seeding but enlarged liver metastasis. The patient then received three cycles of biweekly gemcitabine and infusional 5-fluorouracil and leucovorin (gemcitabine, 1000 mg/m2, and 5-fluorouracil, 2400 mg/m2, plus leucovorin, 300 mg/m2, in a 48-hour infusion). However, intermittent hemoptysis developed and was followed by an episode with dyspnea and impaired gas exchange. The subsequent CT scan showed progression of the mediastinal mass, liver metastasis, and right hilar lymphadenopathy, with suspected invasion of the right bronchus (Fig. 2A and 2C). Palliative radiotherapy (33 Gy in 10 fractions) to the thymic tumor and right hilar lymphadenopathy for symptomatic and potentially life-threatening tumor bleeding was performed. The patient also received nivolumab (2 mg/kg repeated every 3 weeks), and the hemoptysis subsided thereafter. A CT scan after the fourth cycle of nivolumab showed a partial response, including the liver metastasis, which was not within the radiation field (Fig. 2). The patient experienced only grade 1 skin rash, which was controlled by topical agents. Biomarkers predictive of response to nivolumab were tested by immunohistochemical staining, which disclosed 1% (composed of tumor cells and immune cells) PD-L1 expression (SP142) (Fig. 3) and proficient mismatch repair with a preserved mutS homolog 6, PMS1 homolog 2, mismatch repair system component, and mutL homolog 1 expression (see Fig. 3). Our case suggests that nivolumab may also be an efficacious and safe option in the treatment of metastatic thymic carcinoma. Currently, two phase II trials examining the efficacy of pembrolizumab in thymic epithelial tumors are ongoing, with response rates of approximately 24%.4Giaccone G. Thompson J. McGuire C. et al.Pembrolizumab in patients with recurrent thymic carcinoma: results of a phase II study.J Clin Oncol. 2017; 35 ([abstract]): 8573Google Scholar, 5Cho J. Ahn M.J. Yoo K.H. et al.A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor.J Clin Oncol. 2017; 35 ([abstract]): 8521Google Scholar High rates of immune-related adverse events were also reported by Cho et al.5Cho J. Ahn M.J. Yoo K.H. et al.A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor.J Clin Oncol. 2017; 35 ([abstract]): 8521Google Scholar A phase II trial studying nivolumab in patients with World Health Organization (WHO) type B3 and C thymomas (NIVOTHYM, NCT03134118) is expected to start accrual in 2018. We thank the patient for consenting to this publication.

Unsuccessful rechallenge with nivolumab in a patient with advanced non-small cell lung cancer who had a 6-year complete response and treatment-free period: Case report

Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study

Nivolumab Rechallenge After Immune-related Adverse Events in Patients With Unresectable Advanced or Recurrent Esophageal Cancer

Predictive markers of response to immune checkpoint inhibitor rechallenge in metastatic non-small cell lung cancer

Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: a retrospective study

Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review

Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors Following Disease Progression or Relapse

Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study

Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report

Response to Nivolumab As Salvage Therapy in a Patient with Thymic Carcinoma

Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study

Retreatment with Immune Checkpoint Inhibitors in the New Scenario of Immunotherapy in Non-Small Cell Lung Cancer

Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort

Current Status in Rechallenge of Immunotherapy

Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer: a case report

Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions

Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer

Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis

Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer

Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study